ChromaDex Corporation (OTC Bulletin Board: CDXC), announced today that the Company has been awarded the 2010 North American Health Ingredients Most Promising Ingredient of the Year award by the independent research company, Frost & Sullivan, for its proprietary branded ingredient pTeroPure™ Pterostilbene.
"We are extremely pleased that Frost & Sullivan has recognized the potential of pTeroPure in the marketplace," said Frank Jaksch, ChromaDex CEO. "The award confirms pTeroPure's ability to produce sustained value across multiple market channels by providing distinct, science-based health benefits to a broad range of consumer segments. Furthermore, it validates our corporate strategy of continuing to develop and commercialize novel, proprietary ingredients that are grounded in science and focused on enhancing health. We accept the award with enthusiasm and look forward to the exciting future that awaits pTeroPure."
Frost & Sullivan benchmarked ChromaDex against key competitors across four criteria: unique selling features, continued research efforts, current market acceptance and growth potential, and marketing and promotion endeavors.
pTeroPure Pterostilbene is a naturally-occurring compound found in blueberries and belonging to a group of compounds called phytoalexins, which are produced by plants to fight infection from bacteria or fungi. Numerous published studies have shown that the compound has the ability to combat various health problems including diabetes, high blood pressure, high cholesterol, oxidative stress, and neurodegeneration.
"The highly beneficial properties of pterostilbene are expected to guarantee huge market potential for pterostilbene in the human nutrition industry," said Sneha Pasricha, Frost & Sullivan senior research analyst.
ChromaDex has licensed two patents pending from the USDA through the University of Mississippi, a process patent from a manufacturing partner, and is filing a patent in collaboration with the University of California at Irvine. The two USDA patents focus on the ability of pterostilbene to reduce blood lipoprotein levels through PPAR-alpha activation and pterostilbene's effect on oxidative stress and cognitive and memory enhancement, respectively. ChromaDex has a strategy to expand its patent portfolio related to pterostilbene with a number of additional filings.
The company is currently involved in an on-going clinical study with the University of Mississippi which will evaluate the effect of pterostilbene in patients with cholesterol and blood pressure problems.
"With such strengthening Intellectual Property body, pterostilbene is expected to expand into various health markets including anti-aging, heart health and memory enhancement," said Pasricha.
Phytoene increases lifespan, reduces oxidative stress and amyloid toxicity